208 results about "Antigen presentation" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.

The invention discloses a CD40L-IL-2 fusion protein, preparation thereof and application of the CD40L-IL-2 fusion protein in preparation of drugs for treating tumors. The fusion protein comprises a CD40L trimer or a variant thereof, and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The present invention discloses a lactoferrin composition and its application for improving immunity by regulating macrophage immune activity, and belongs to the technical field of functional compositions. The present invention obtains a lactoferrin composition with regulating macrophage immune activity by compounding lactoferrin, α-lactalbumin, N-acetylneuraminic acid and yeast β-glucan in a specific ratio, the raw material of the composition is easy to obtain, and four components work together to significantly enhance its phagocytic activity without changing the activity of macrophages, regulate the polarization state of macrophages in inflammatory response, inhibit macrophages from polarizing to pro-inflammatory M1 type, and promote macrophages to polarize to anti-inflammatory M2 type; At the same time, the composition can also enhance the antigen presentation ability of macrophages and the activation of immune T cells, and improve body immunity. Therefore, the composition provided by the present invention can be used to prepare health products, food or medicines, etc. that improve immunity.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention provides a preparation method of a novel PEDV (porcine epidemic diarrhea virus) subunit vaccine, and belongs to the technical field of biology. The novel PEDV subunit vaccine is prepared by adopting a method comprising the following steps: (1) treating lactococcus lactis by using a high-pressure damp-heat method to obtain peptidoglycan particles; (2) treating the peptidoglycan particles by adopting an ultrahigh-pressure microjet technology to obtain a peptidoglycan carrier with the particle size of 280-850nm; and (3) mixing the peptidoglycan carrier with a PEDV subunit antigen of which the amino acid sequence is SEQ ID NO: 1 to obtain the novel PEDV subunit vaccine. The novel PEDV subunit vaccine comprises a peptidoglycan carrier with a specific size, can improve the in-vivo presentation efficiency of an antigen and rapidly induce efficient body fluid and mucous membrane immune response, and is of great significance to research and development of vaccines for porcine epidemic diarrhea diseases and the like.

The invention belongs to the technical field of cellular immunity, and particularly relates to calcium-doped manganese phosphate engineered red blood cells based on a biomimetic mineralization technology and application of the calcium-doped manganese phosphate engineered red blood cells in immunotherapy. Calcium ions, manganese phosphate, acidic polypeptide and a carboxyl activator are deposited on the surfaces of red blood cells, the acidic polypeptide provides a negative electricity environment, the concentration of calcium and manganese on red blood cell membranes is increased, and a mineralization layer of calcium ions and manganese ions is formed; the carboxyl activator can activate carboxyl of amino acid on acidic polypeptide and is covalently bound with other molecules; calcium can improve the stability of the manganese phosphate crystal, optimize the release of manganese ions and activate a cGAS-STING pathway in the DC; the natural half-life period of red blood cells reaches 120 days, rapid clearing of the liver can be avoided, the aged red blood cells are swallowed by spleen DC, and cross presentation of antigens is promoted. The calcium-doped manganese phosphate engineered erythrocyte provided by the invention can promote the maturation, migration, homing and antigen presentation functions of dendritic cells, and enhance the ability of the dendritic cells to activate CD8 + T cells.

The invention discloses a nucleic acid tetrahedron nanostructure as well as a preparation method and application thereof. The nucleic acid tetrahedron nanostructure is composed of circRNA for coding an antigen, an ISD chain and two specific single-stranded DNA sequences, is simple and easy to prepare, can enter cells through cell membrane microfossa mediated endocytosis without the help of a transfection reagent, and is positioned to lysosome. The nanostructure is split to release circRNA coding antigen protein, and the circRNA coding antigen protein is delivered to APC and ISD chains in drainage lymph nodes (dLN) to activate cGAS-STING pathways, so that antigen presentation and immune activation are synergistically enhanced, T cells are efficiently and continuously activated, and the effect of tumor immunotherapy is achieved.

The invention discloses a method for preparing a multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method, and relates to a preparation method of a nano-hydroxyapatite-based tumor vaccine. The invention aims to solve the problems of low antigen presentation efficiency of existing tumor vaccines and complex preparation process of nano vaccines based on tumor cell membranes. The preparation method comprises the following steps: 1, preparing small-particle-size calcium-based nanoparticles; and 2, synthesizing the HAP NV (at) DOX nano compound. The preparation method is used for preparing the multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method.

The application provides a kind of HLA-A24:02 APC cell preparation method and application, it is related to cell preparation technical field.The present application constructs the APC cell (K562-HLA-A24:02) that can replace HLA-A24:02 subtype DC cell, fills the blank of HLA-A24:02 subtype special engineering APC cell, and the cell can realize the antigen presentation function consistent with natural HLA-A24:02 subtype DC cell, provides special tool cell for the immune research for the HLA subtype;The present application constructs APC cell with K562 cell line as base, K562 cell can be in vitro permanent passage amplification, without repeatedly separating and inducing DC cell from human peripheral blood, reduces the use amount of peripheral blood, reduces the raw material dependence and cost of cell acquisition, while avoiding the influence of individual difference of peripheral blood source on experimental results.

Abstract Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell. Abstract 2018 / 22761 oM - cell Target ml Target cell cell cell Target Target Target SUBSTITUTE SHEET (RULE 26) cell cell cell Target Target cell cell 1 / 28 my Isolate recognized cell Library of target cells target cells and displaying different Add T cells from sample sequence antigens antigens of interest. CTLs deliver cytotoxic granules to target cells displaying cognate antigen FIG. 1 PCT / US2018 / 036663 20 26 20 53 56 07 J ul 2 02 6 2 0 2 6 2 0 5 3 5 6 0 7 J u l 2 0 2 6 2 0 1 8 / 2 2 7 6 1 o M a n d m y 1 / 2 8 m y L i b r a r y o f t a r g e t c e l l s d i s p l a y i n g d i f f e r e n tA d d T c e l l s f r o m s a m p l e of interest. CTLs deliver c y t o t o x i c g r a n u l e s t o t a r g e t c e l l s d i s p l a y i n g c o g n a t e a n t i g e n P C T / U S 2 0 1 8 / 0 3 6 6 6 3

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

The invention belongs to the technical field of cancer immunotherapy, and particularly relates to iterative radiation-resistant tumor cell debris, a preparation method thereof and an application thereof in tumor resistance. The anti-radiation tumor cells generated by repeated radiation exposure show higher TMB (Tetramethylbenzidine) and induce stronger immunoreaction, so that a personalized vaccine is developed based on the method, and the frozen fragment vaccine is obtained by freeze thawing and inactivation of the radiation-resistant tumor cells. The RR-FDV exhibits enhanced immunogenicity as compared to a conventional radiosensitive counterpart. In the present disclosure, RR-FDV exhibits superior activation of antigen presenting cells, while in vivo, it recruits more dendritic cells to the vaccination site, promotes DC-mediated antigen presentation, and induces stronger antigen-specific T cell toxicity.

The invention discloses a nucleic acid vaccine based on different forms of nano-aluminum adjuvants and application thereof, the nucleic acid vaccine is composed of an inner core, a middle layer and a shell from inside to outside in sequence, the inner core is a compound of a cationic polymer and nucleic acid, the middle layer is an anionic polymer, and the shell is a continuous or discontinuous nano-aluminum coating layer. The nano-aluminum-coated nucleic acid delivery system provided by the invention is used for preparing vaccines, can effectively activate antigen presenting cells and promote antigen presentation, so that humoral immunity and cellular immunity processes of an organism are simultaneously activated, the tumor immunotherapy effect is enhanced, and the nano-aluminum-coated nucleic acid delivery system has relatively high clinical use value.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The invention discloses an unknown network threat immunodetector generation method and device, and relates to the technical field of network security, and the method comprises the steps: S1, obtaining a training sample; s2, performing antigen presentation to obtain a training autoantigen set and a training non-autoantigen set; s3, extracting an edge autoantigen; s4, deducing an unknown non-autologous antigen by using the edge autoantigen; s5, carrying out tolerance training on unknown non-autoantigen and autoantigen, adding the antigen subjected to tolerance training as a mature antibody into the t-th generation non-autoantigen set, and generating a network attack detector; s6, judging whether t reaches a preset number of times, and if so, ending; otherwise, entering S7; s7, enabling t + 1 to be equal to t, and returning to S3; according to the method, the autoevolution of the detector is realized, and the immune detector capable of detecting unknown is generated, so that the immune detector can dynamically adapt to an unknown network attack mode; according to the method, an edge benign detector can adaptively optimize and construct an unknown attack process, and unknown network threats can be efficiently and accurately detected.

Provided is a method of using circular RNA as vaccine to treat cancer and design strategy to elicit specific and robust T cell response by promoting antigen presentation.

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

Highly specific T cells and T-cell receptors (TCRs) specific to a pathogen associated with an infectious disease can be generated by ex vivo induction or expansion, which can be useful for developing therapeutics such as vaccines for infectious diseases and determining antigen presentation in vitro. The present disclosure provides malaria-specific TCRs and nucleic acid encoding the TCRs, methods of making T cells specific for an infectious disease, methods of identifying TCRs, and methods of using the same for determining whether a vaccine induces T cell specific immune response, whether an epitope sequence is presented, and whether an antigen is recognizable by TCRs.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

The application relates to an aptamer-membrane fusion liposome nanomedicine as well as a preparation method and application thereof, and belongs to the technical field of nanomedicine preparation. The aptamer-membrane fusion liposome nanomedicine disclosed by the application is formed based on the affinity between the cholesterol (Chol) at the 3' end of an aptamer and a liposome, has small bond energy, good spatial orientation, high selectivity and reversibility. In the aptamer-membrane fusion liposome nanomedicine, the liposome can be fused with a membrane, co-loaded auranofin (AUR) has the functions of promoting cell iron death and sensitizing radiotherapy, the immunoadjuvant aptCpG can target dendritic cells (DCs), stimulate the functions of DCs maturation and antigen presentation, and further activate subsequent immune responses. The bionic liposome nanomedicine provides a new way for improving the effectiveness of clinical malignant tumor treatment.

The present application relates to a kind of universal preparation method for presenting tumor antigen and highly activated T cell exosome, belong to biomedical and immunotherapy technical field.The present application described method is first synthesized the tumor antigen specificity nano stimulant capable of activating dendritic cell, makes dendritic cell carry IFN-β, expresses specific tumor-related antigen and costimulatory molecule, to solve the problems, such as low antigen presentation efficiency, T cell activation deficiency and high cost of individualized treatment in the existing tumor immunotherapy method.Exosome is extracted from the supernatant of the above dendritic cell culture.The preparation method of the present application not only significantly improves the efficiency of exosome as antigen presentation carrier, effectively and specifically stimulates T cell, but also reduces the preparation cost, provides more effective general solution for tumor immunotherapy, has wide application prospect and clinical value.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The invention relates to the technical field of vaccine preparation, and particularly discloses an H1-pIL-24 / pCAIX nano vaccine, an anti-tumor medicine and application, and the H1-pIL-24 / pCAIX nano vaccine is prepared through the following steps: constructing an expression plasmid containing an mIL-24 sequence and an expression plasmid containing a CAIX sequence; the expression plasmid containing the mIL-24 sequence and the expression plasmid containing the CAIX sequence are respectively transformed into competent cells and cultured, two obtained recombinant plasmids are mixed with the H1 nano carrier, and the H1-pIL-24 / pCAIX nano vaccine is obtained. The H1-pIL-24 / pCAIX nano vaccine can significantly inhibit the growth of tumors and the occurrence of pulmonary metastasis, improve DC uptake and antigen presentation, enhance the expression of CD8 cells and IFN-gamma, enhance the expression of central memory T cells, and effectively stimulate the tumor immune response of mice.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The invention relates to the field of immune cells. According to the preparation method and application of the novel immune cell, lentivirus containing DNA molecules subjected to gene modification is used for transfecting cells in peripheral blood of mammals, so that the cells can be passaged for multiple times, and the cells have the antigen presenting capacity and the capacity of activating and amplifying natural killer cells. After the cell is further genetically modified, better transmembrane transfer, antigen presentation and natural killer cell activation can be realized. After gene modification, the cell and different cytokines or small molecules jointly activate and amplify mononuclear cells to obtain a larger number of natural killer cells with higher purity, epigenetics are regulated and controlled to change the receptor and ligand expression quantity of the natural killer cells, and then the cytotoxicity of effector cells is improved. The invention can be used for preparing antigen presenting cells and CTL cells aiming at different antigens and an application method. The cells and the using method have wide application prospects in the aspects of prevention and treatment of tumors and infectious diseases.

The invention discloses a cGAS-STING pathway activated tumor vaccine based on X-type framework nucleic acid, and belongs to the technical field of biological medicine and immune engineering. The vaccine is composed of X-type framework nucleic acid and alkynyl modified antigen peptide, the X-type framework nucleic acid is of a four-arm Halide knot structure formed by self-assembly of four oligonucleotide chains, and the antigen peptide is coupled to the oligonucleotide chains. According to the invention, the unique multi-branch topological structure of the X-type framework nucleic acid is utilized to enhance the binding stability with cGAS and efficiently activate a cGAS-STING signal channel without additional adjuvants; meanwhile, stable presentation and efficient delivery of the antigen peptide are realized, dendritic cell maturation and antigen presentation are promoted, and strong antigen specific CD8 + T cell immune response is induced. The vaccine shows a remarkable tumor inhibition effect in tumor prevention and treatment models, has the advantages of stable structure, high immunization efficiency, good safety and the like, and provides a novel vaccine platform for tumor immunotherapy.